You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
以嶺藥業(002603.SZ):連花清瘟膠囊(顆粒)列入第九版新冠病毒肺炎診療方案
格隆匯 03-17 18:49

格隆匯3月17日丨以嶺藥業(002603.SZ)公佈,近日,國家衞生健康委和國家中醫藥管理局聯合發佈了《新型冠狀病毒肺炎診療方案(試行第九版)》。由公司生產的專利中藥連花清瘟膠囊和公司全資子公司北京以嶺藥業有限公司生產的專利中藥連花清瘟顆粒被該方案列為中醫治療醫學觀察期、臨牀治療期(確診病例)輕型和普通型推薦用藥。

連花清瘟膠囊(顆粒)為公司的主導產品、國家基本藥物目錄和國家醫保目錄(甲類)品種,主要用於感冒、流感相關疾病的治療,曾先後多次被國家衞生健康委、國家中醫藥管理局列入感冒、流感相關疾病診療方案。2020年4月12日,國家藥品監督管理局批准連花清瘟膠囊(顆粒)在原批准適應症的基礎上,增加“新型冠狀病毒肺炎輕型、普通型”的新適應症。

自新冠疫情發生以來,連花清瘟膠囊(顆粒)已連續被《新型冠狀病毒肺炎診療方案(試行第四/五/六/七/八版)》列為中醫治療醫學觀察期推薦用藥。本次發佈的《新型冠狀病毒肺炎診療方案(試行第九版)》中,除將連花清瘟膠囊(顆粒)繼續列為中醫治療醫學觀察期推薦用藥外,還將其列為臨牀治療期(確診病例)輕型和普通型推薦用藥。

2021年前三季度,公司連花清瘟產品實現營業收入33.7億元,佔公司總營業收入的41.6%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account